Top 75 medical and healthcare startups in France
Jan 04, 2026
|
Like
16
1
Funding: €135M
Adcytherix is dedicated to creating and advancing innovative antibody-drug conjugates (ADCs) that go beyond current limitations. By combining state-of-the-art payload innovation with deep ADC development expertise, the company aims to revolutionize targeted therapies for cancer and other conditions of significant unmet medical need. Most existing ADCs rely on two classes of payloads, tubulin and topoisomerase 1 inhibitors. Adcytherix is investigating novel payloads classes with mechanisms of action selected to overcome tumor resistance while enhancing safety, with the potential to manage a wider range of cancers. Adcytherix is guided by a experienced management team and is backed by a network of top-tier experts in the field of ADC development.
Adcytherix is dedicated to creating and advancing innovative antibody-drug conjugates (ADCs) that go beyond current limitations. By combining state-of-the-art payload innovation with deep ADC development expertise, the company aims to revolutionize targeted therapies for cancer and other conditions of significant unmet medical need. Most existing ADCs rely on two classes of payloads, tubulin and topoisomerase 1 inhibitors. Adcytherix is investigating novel payloads classes with mechanisms of action selected to overcome tumor resistance while enhancing safety, with the potential to manage a wider range of cancers. Adcytherix is guided by a experienced management team and is backed by a network of top-tier experts in the field of ADC development.
2
Funding: $1.1B
Valneva is a pharmaceutical company focused on the prevention of infectious diseases with significant unmet medical need.
Valneva is a pharmaceutical company focused on the prevention of infectious diseases with significant unmet medical need.
3
Funding: $816.5M
Doctolib is an online and mobile booking platform that helps to find a specialist doctor nearby and make an appointment.
Doctolib is an online and mobile booking platform that helps to find a specialist doctor nearby and make an appointment.
4
Funding: €666M
Alan wants to make health insurance as simple as subscribing to a software-as-a-service product. It starts with clear pricing and transparent reimbursement policies.
Alan wants to make health insurance as simple as subscribing to a software-as-a-service product. It starts with clear pricing and transparent reimbursement policies.
5
Funding: $393.5M
Cellectis has developed genome editing technology TALEN, which enables it to create more affordable, ready-to-use allogeneic CAR T-cell therapies. Its technology offers protection against graft-versus-host disease, reduces the risk of rejection and improves safety by integrating a self-destruct mechanism. Using this technology, the company is developing a pipeline of several candidates against non-Hodgkin's lymphoma, large B-cell lymphoma, renal cell carcinoma and melanoma. Cellectis is also advancing PulseAgile technology, which uses electroporation (controlled electric fields) to deliver messenger RNA molecules into cells. It utilizes a unique electric field waveform, which, combined with a proprietary buffer solution, allows molecules such as nucleases to effectively penetrate cells while maintaining high cell viability.
Cellectis has developed genome editing technology TALEN, which enables it to create more affordable, ready-to-use allogeneic CAR T-cell therapies. Its technology offers protection against graft-versus-host disease, reduces the risk of rejection and improves safety by integrating a self-destruct mechanism. Using this technology, the company is developing a pipeline of several candidates against non-Hodgkin's lymphoma, large B-cell lymphoma, renal cell carcinoma and melanoma. Cellectis is also advancing PulseAgile technology, which uses electroporation (controlled electric fields) to deliver messenger RNA molecules into cells. It utilizes a unique electric field waveform, which, combined with a proprietary buffer solution, allows molecules such as nucleases to effectively penetrate cells while maintaining high cell viability.
6
Funding: $315.9M
Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases. We are focussing on diseases with a high unmet medical need where either no treatments are available, such as NASH and Systemic Sclerosis, or the current standard of care leaves important manifestations of the diseases unaffected, as it is the case in many lysosomal storage diseases.
Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases. We are focussing on diseases with a high unmet medical need where either no treatments are available, such as NASH and Systemic Sclerosis, or the current standard of care leaves important manifestations of the diseases unaffected, as it is the case in many lysosomal storage diseases.
7
Funding: $304.1M
OWKIN is the AI startup that uses machine learning to augment medical and biology research. Our proprietary platform, OWKIN Socrates, uses machine learning technology to integrate biomedical images, genomics and clinical data to discover biomarkers and mechanisms associated with diseases and treatment outcomes.
OWKIN is the AI startup that uses machine learning to augment medical and biology research. Our proprietary platform, OWKIN Socrates, uses machine learning technology to integrate biomedical images, genomics and clinical data to discover biomarkers and mechanisms associated with diseases and treatment outcomes.
8
Funding: $277.5M
Genfit SA, a biopharmaceutical engages in the research and development of drugs for the prevention and treatment.
Genfit SA, a biopharmaceutical engages in the research and development of drugs for the prevention and treatment.
9
Funding: $274.4M
We are a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.
We are a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.
10
Funding: €258.1M
The mission of every team member at Carmat is to contribute to the development of innovative artificial organs – the artificial heart today, tomorrow other vital organs – to treat millions of patients affected by advanced disease of these organs and to restore their normal life.
The mission of every team member at Carmat is to contribute to the development of innovative artificial organs – the artificial heart today, tomorrow other vital organs – to treat millions of patients affected by advanced disease of these organs and to restore their normal life.
11
Funding: $219.7M
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer (OncoMimics™ peptides). Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer (OncoMimics™ peptides). Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.
12
Funding: $210M
Tissium invents the next generation of synthetic polymers for tissue reconstruction
Tissium invents the next generation of synthetic polymers for tissue reconstruction
13
Funding: €193.1M
ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint modulators.
ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint modulators.
14
Funding: $179.5M
HiFiBiO Therapeutics is biotherapeutics company mobilizing the human immune system to combat disease. We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. We also aspire to benefit patients through open-innovation partnerships with industry and academia.
HiFiBiO Therapeutics is biotherapeutics company mobilizing the human immune system to combat disease. We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. We also aspire to benefit patients through open-innovation partnerships with industry and academia.
15
Funding: $170.6M
Wandercraft develops and sells the first exoskeleton to walk self-balanced, for inpatient rehab and outpatient daily life.
Wandercraft develops and sells the first exoskeleton to walk self-balanced, for inpatient rehab and outpatient daily life.
16
Funding: €132.3M
Diabeloop is a medical device company for diabetes and closed-loop system.
Diabeloop is a medical device company for diabetes and closed-loop system.
17
Funding: $127.6M
SparingVision is a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa.
SparingVision is a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa.
20
Funding: $114.7M
Nabla is the developer of Nabla Copilot, an ambient AI that helps clinicians enjoy care again.
Nabla is the developer of Nabla Copilot, an ambient AI that helps clinicians enjoy care again.
21
Funding: €103.5M
ENYO Pharma is a clinical stage Biotech with a unique drug discovery engine inspired by viruses. In particular it develops drug for Chronic Hepatitis B.
ENYO Pharma is a clinical stage Biotech with a unique drug discovery engine inspired by viruses. In particular it develops drug for Chronic Hepatitis B.
22
Funding: $109.5M
Aqemia is aiming to invent better therapeutic molecules faster. We do that by combining generative AI and quantum-inspired statistical mechanics algorithms to predict affinity between therapeutic target and drugs with experimental accuracy and 10’000 times faster than best softwares.
Aqemia is aiming to invent better therapeutic molecules faster. We do that by combining generative AI and quantum-inspired statistical mechanics algorithms to predict affinity between therapeutic target and drugs with experimental accuracy and 10’000 times faster than best softwares.
23
Funding: €101.6M
MaaT Pharma (Microbiota as a Therapy) is intended to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis.
MaaT Pharma (Microbiota as a Therapy) is intended to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis.
24
Funding: €91M
SafeHeal develops Colovac, an innovative solution for the protection of digestive anastomosis, designed to reduce anastomotic complications.
SafeHeal develops Colovac, an innovative solution for the protection of digestive anastomosis, designed to reduce anastomotic complications.
25
Funding: $91.2M
Resilience Care is building a software-based solution for cancer treatment providers and patients.
Resilience Care is building a software-based solution for cancer treatment providers and patients.
26
Funding: $89M
Lifen aims to improve the quality of healthcare by facilitating access to digital innovation, benefiting both doctors and patients. The startup has built its success up to now on the digitization of medical reports, based on proven technologies, and fulfilling the most stringent security requirements.
Lifen aims to improve the quality of healthcare by facilitating access to digital innovation, benefiting both doctors and patients. The startup has built its success up to now on the digitization of medical reports, based on proven technologies, and fulfilling the most stringent security requirements.
27
Funding: €81M
UroMems ambition is to offer to the patients suffering from severe urinary incontinence a simple and efficient innovative solution. UroMems is currently developing an active implantable medical device which compensates for sphincter insufficiency.
UroMems ambition is to offer to the patients suffering from severe urinary incontinence a simple and efficient innovative solution. UroMems is currently developing an active implantable medical device which compensates for sphincter insufficiency.
28
Funding: $74.7M
A unique platform to engineer and intervene on the microbiome. Eligobiotics are a platform technology that can be programmed to leverage the existing microbial populations in the gut, lungs, vagina, skin, etc. This technology can enable a targeted diagnosis, editing, and functionalization of human or animal microbiomes.
A unique platform to engineer and intervene on the microbiome. Eligobiotics are a platform technology that can be programmed to leverage the existing microbial populations in the gut, lungs, vagina, skin, etc. This technology can enable a targeted diagnosis, editing, and functionalization of human or animal microbiomes.
29
Funding: $73.6
Volta Medical has developed an AI-enabled software for interventional cardiac electrophysiology
Volta Medical has developed an AI-enabled software for interventional cardiac electrophysiology
30
Funding: $69.6M
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.
31
Funding: $66.9M
Mauna Kea Technologies specializes in designing, developing, and selling optical biopsy devices and tools.
Mauna Kea Technologies specializes in designing, developing, and selling optical biopsy devices and tools.
32
Funding: $57M
Dreem is a neurotechnology company building consumer technology that stimulates the brain to enhance human potential. The company's product, Dreem is a wearable device that enhances the quality of deep sleep. The device monitors brainwaves, analyzes user's sleep and stimulates the brain with sound in order to extend the amount of deep sleep, improving human performance throughout the day.
Dreem is a neurotechnology company building consumer technology that stimulates the brain to enhance human potential. The company's product, Dreem is a wearable device that enhances the quality of deep sleep. The device monitors brainwaves, analyzes user's sleep and stimulates the brain with sound in order to extend the amount of deep sleep, improving human performance throughout the day.
33
Funding: €49.3M
Egle Therapeutics is a biotechnology company focused on developing immunotherapies for oncology and autoimmune diseases.
Egle Therapeutics is a biotechnology company focused on developing immunotherapies for oncology and autoimmune diseases.
34
Funding: €43M
SeqOne is a next generation genomic analysis for next generation healthcare.
SeqOne is a next generation genomic analysis for next generation healthcare.
35
Funding: $44.7M
Gleamer develops an AI-powered software to enhance radiologists’ productivity.
Gleamer develops an AI-powered software to enhance radiologists’ productivity.
37
Funding: $43.3M
NOVACYT develops cellular diagnostics with a growing portfolio of cancer and infectious disease products and services.
NOVACYT develops cellular diagnostics with a growing portfolio of cancer and infectious disease products and services.
38
Funding: $38.9M
Synapse Medicine offers a medication intelligence platform for healthcare professionals. It uses natural language processing to analyze and classify medication information
Synapse Medicine offers a medication intelligence platform for healthcare professionals. It uses natural language processing to analyze and classify medication information
39
Funding: $35.5M
Inato allows sponsors and CROs to predict and tailor their recruitment strategy before the launch of clinical trials to reduce timelines.
Inato allows sponsors and CROs to predict and tailor their recruitment strategy before the launch of clinical trials to reduce timelines.
40
Funding: €32.6M
Incepto Medical is a Medical imaging solution based on artificial intelligence
Incepto Medical is a Medical imaging solution based on artificial intelligence
41
Funding: €28M
Keranova develops instruments for ophthalmic surgery, i.e. Ultra Fast lasers using photonic science and robotics
Keranova develops instruments for ophthalmic surgery, i.e. Ultra Fast lasers using photonic science and robotics
42
Funding: $27.5M
Implicity developed a universal remote monitoring platform for cardiac patients with connected pacemakers and implantable defibrillators.
Implicity developed a universal remote monitoring platform for cardiac patients with connected pacemakers and implantable defibrillators.
43
Funding: $26.1M
Therapixel is a software company specialized in artificial intelligence for medical image analytics. Therapixel makes touchless image navigation system designed for operating theaters: interventional radiology or surgery.
Therapixel is a software company specialized in artificial intelligence for medical image analytics. Therapixel makes touchless image navigation system designed for operating theaters: interventional radiology or surgery.
44
Funding: $25.8M
Chipiron is a company that designs, manufactures, and markets a new generation of portable, inexpensive and powerful MRI machines.
Chipiron is a company that designs, manufactures, and markets a new generation of portable, inexpensive and powerful MRI machines.
45
Funding: $24.8M
Remedee is the next generation pain relief offering a new and individualized therapy to every patient.
Remedee is the next generation pain relief offering a new and individualized therapy to every patient.
46
Funding: €22M
To treat Aortic Stenosis, Cardiawave has developed a non-invasive, real-time image-guided medical device using a cutting-edge ultrasound technology, known as Pulsed Cavitational Ultrasound Therapy (PCUT).
To treat Aortic Stenosis, Cardiawave has developed a non-invasive, real-time image-guided medical device using a cutting-edge ultrasound technology, known as Pulsed Cavitational Ultrasound Therapy (PCUT).
47
Funding: €22.3M
Exeliom Biosciences develops a bacterial treatment for inflammatory bowel diseases. It's intended to rebalance the gut microbiome through the delivery of Faecalibacterium prausnitzii, one of the most abundant species of bacteria in the gut.
Exeliom Biosciences develops a bacterial treatment for inflammatory bowel diseases. It's intended to rebalance the gut microbiome through the delivery of Faecalibacterium prausnitzii, one of the most abundant species of bacteria in the gut.
48
Funding: $23M
Zoī is a science-backed holistic approach for health and wellness. Zoi wants to give you personalized insights so that you can improve your overall health over the long run.
Zoī is a science-backed holistic approach for health and wellness. Zoi wants to give you personalized insights so that you can improve your overall health over the long run.
49
Funding: $23.1M
By applying the latest research in Artificial intelligence, Cardiologs provides a web solution to streamline this process at large scale, enabling the highest diagnostic yield, for the least physician effort.
By applying the latest research in Artificial intelligence, Cardiologs provides a web solution to streamline this process at large scale, enabling the highest diagnostic yield, for the least physician effort.
50
Funding: $21.2M
AZmed offers powerful AI-aided diagnosis tool that detects all types of fractures in radiography
AZmed offers powerful AI-aided diagnosis tool that detects all types of fractures in radiography
